BOLT (Bolt Biotherapeutics) Institutional Ownership: 32.44% (As of Jul. 11, 2026)


BOLT Bolt Biotherapeutics Inc BOLT
53 GF Score
Price $3.78
GF Value $9.06
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Bolt Biotherapeutics Institutional Ownership?

Bolt Biotherapeutics BOLT -5.03% 53 Institutional Ownership is 32.44% as of Jul. 11, 2026. GuruFocus rates BOLT with a GF Score™ of 53/100 and a GF Value™ of $9.06 (Possible Value Trap). The stock has 4 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Bolt Biotherapeutics's institutional ownership is 32.44%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Bolt Biotherapeutics's Insider Ownership is 6.24%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Bolt Biotherapeutics's Float Percentage Of Total Shares Outstanding is 99.93%.

Bolt Biotherapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Bolt Biotherapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bolt Biotherapeutics Institutional Ownership Chart

Bolt Biotherapeutics Historical Data

The historical data trend for Bolt Biotherapeutics can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 5.64 4.42 1.89 2.18 2.18 2.26 2.63 2.60 2.60 2.60
BOLT
53GF Score
Bolt Biotherapeutics Inc BOLT
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bolt Biotherapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 32.44% mean?
Bolt Biotherapeutics (BOLT) has a Institutional Ownership of 32.44% as of Jul. 11, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Bolt Biotherapeutics and its competitors.
Is Bolt Biotherapeutics' Institutional Ownership too high?
Bolt Biotherapeutics' current Institutional Ownership is 32.44%. Overall, Bolt Biotherapeutics has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bolt Biotherapeutics' Institutional Ownership compare to AIM and ERNA?
Bolt Biotherapeutics' Institutional Ownership of 32.44% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Bolt Biotherapeutics and its competitors. Bolt Biotherapeutics's current Institutional Ownership is 32.44%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bolt Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Bolt Biotherapeutics (BOLT) is currently considered Possible Value Trap. The stock's GF Value™ is $9.06, compared to a current price of $3.78 — trading 58.3% below its estimated fair value. The current Institutional Ownership is 32.44%. Bolt Biotherapeutics' overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Bolt Biotherapeutics (BOLT), the current Institutional Ownership is 32.44% as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bolt Biotherapeutics (BOLT) Overvalued in 2026?

Based on GuruFocus' analysis, Bolt Biotherapeutics stock appears to be undervalued. The current stock price of $3.78 is trading 58.3% below its estimated GF Value™ of $9.06. GuruFocus considers Bolt Biotherapeutics to be Possible Value Trap.

Key valuation signals for BOLT:

  • Institutional Ownership: 32.44%
  • GF Value™: $9.06 vs. price of $3.78 (58.3% below fair value)
  • GF Score™: 53/100 with 4 warning signs

No single metric tells the full story. See the BOLT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bolt Biotherapeutics Business Description

Address 900 Chesapeake Drive, Redwood City, CA, USA, 94063
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.
53GF Score

Get the complete analysis for BOLT

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.78
Price
$9.06
GF Value